[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@BPharmCatalyst Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::56121651.png) @BPharmCatalyst BioPharmCatalyst

BioPharmCatalyst posts on X about $gnpx, $evax, $cdt, $ndra the most. They currently have XXXXXX followers and XXX posts still getting attention that total XX engagements in the last XX hours.

### Engagements: XX [#](/creator/twitter::56121651/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::56121651/c:line/m:interactions.svg)

- X Week XXXXX -XX%
- X Month XXXXXX -XX%
- X Months XXXXXXXXX +66%
- X Year XXXXXXXXX -XX%

### Mentions: X [#](/creator/twitter::56121651/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::56121651/c:line/m:posts_active.svg)

- X Week XX +14%
- X Month XX -XX%
- X Months XXX -XXXX%
- X Year XXX +22%

### Followers: XXXXXX [#](/creator/twitter::56121651/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::56121651/c:line/m:followers.svg)

- X Week XXXXXX +0.13%
- X Month XXXXXX +0.79%
- X Months XXXXXX +3.50%
- X Year XXXXXX +5.30%

### CreatorRank: undefined [#](/creator/twitter::56121651/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::56121651/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::56121651/influence)
---

**Social category influence**
[cryptocurrencies](/list/cryptocurrencies)  XXX% [finance](/list/finance)  XXXX% [stocks](/list/stocks)  XXXX%

**Social topic influence**
[$gnpx](/topic/$gnpx) #16, [$evax](/topic/$evax) #3, [$cdt](/topic/$cdt) #28, [$ndra](/topic/$ndra) 0.85%, [$atxs](/topic/$atxs) #7, [$sprc](/topic/$sprc) #7, [$sbfm](/topic/$sbfm) #14, [$10m](/topic/$10m) #197, [$rapp](/topic/$rapp) 0.43%, [$dnth](/topic/$dnth) XXXX%

**Top accounts mentioned or mentioned by**
[@yusufhameed](/creator/undefined) [@beallucanbe3](/creator/undefined) [@artsstocks](/creator/undefined) [@ti60123bg](/creator/undefined) [@marketwirenews](/creator/undefined) [@hivolbreakouts](/creator/undefined) [@thenorthstar5](/creator/undefined) [@streetcred2017](/creator/undefined) [@meyer_adri74674](/creator/undefined) [@varro_analytics](/creator/undefined) [@brantandre88074](/creator/undefined) [@aponiaanalytics](/creator/undefined) [@ripster47](/creator/undefined) [@augustine_astr](/creator/undefined) [@asset_smind](/creator/undefined) [@ceciliacas81917](/creator/undefined) [@seanluomdphd](/creator/undefined) [@clairefarrngoat](/creator/undefined) [@henrywalke70493](/creator/undefined) [@earthling_777](/creator/undefined)

**Top assets mentioned**
[CheckDot (CDT)](/topic/$cdt) [Summit Therapeutics Inc. Common Stock (SMMT)](/topic/$smmt) [IDEAYA Biosciences, Inc. Common Stock (IDYA)](/topic/$idya) [Akropolis (AKRO)](/topic/$akro) [Apogee Therapeutics, Inc. Common Stock (APGE)](/topic/$apge) [Scholar Rock Holding Corporation Common Stock (SRRK)](/topic/$srrk) [Boston Scientific Corporation (BSX)](/topic/boston-scientific) [Tourmaline Bio, Inc. Common Stock (TRML)](/topic/$trml) [BOLT Token (BOLT)](/topic/$bolt) [Parallax (PLX)](/topic/$plx) [Disc Medicine, Inc. Common Stock (IRON)](/topic/$iron)
### Top Social Posts [#](/creator/twitter::56121651/posts)
---
Top posts by engagements in the last XX hours

"$RAPP announced that its lead candidate RAP-219 met primary and key secondary endpoints in a Phase 2a trial for drug-resistant focal onset seizures demonstrating a XXXX% median seizure reduction and XX% seizure freedom with strong safety and tolerability. $DNTH $SMMT $IDYA $SINT $EDAP $XAIR See More Pre-market Movers"  
[X Link](https://x.com/BPharmCatalyst/status/1965032454596497564) [@BPharmCatalyst](/creator/x/BPharmCatalyst) 2025-09-08T12:40Z 30.4K followers, 3569 engagements


"$CDT announced a 1-for-8 reverse stock split approved by its board aiming to enhance capital-raising flexibility as part of its strategic execution following prior shareholder authorization granted in May 2025. $BJDX $CDT $AKRO $APGE $ATHE $NGNE $TCRT $BDRX $PCSA $GTBP See More Pre-market Movers"  
[X Link](https://x.com/BPharmCatalyst/status/1976266478425915437) [@BPharmCatalyst](/creator/x/BPharmCatalyst) 2025-10-09T12:40Z 30.4K followers, 1966 engagements


"$NDRA secured $XXX million in a private placement led by institutional and crypto investors selling stock and warrants at $XXXX per unit to fund a digital asset treasury strategy focused on Arcas high-conviction DeFi holdings marking a pivot toward blockchain-linked capital deployment alongside its core MASLD/MASH imaging focus. $TRVD $CGEN $RCUS $MNPR $NDRA $SRRK $NBTX $APLT $QNRX $ADTX See More Biotech Updates👇"  
[X Link](https://x.com/BPharmCatalyst/status/1977834368639832089) [@BPharmCatalyst](/creator/x/BPharmCatalyst) 2025-10-13T20:30Z 30.4K followers, 1935 engagements


"$BCRX and $ATXS announced that the companies have entered into a definitive agreement under which BioCryst has agreed to acquire Astria a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases for a mix of cash and stock representing an implied value of $XXXXX per Astria share and approximately $XXX million in enterprise value. $ATXS $IPHA $NDRA $RCKT $SBFM $GDTC $ELAB $GNPX $NBTX $DBVT See More Pre-market Movers"  
[X Link](https://x.com/BPharmCatalyst/status/1978078417846149238) [@BPharmCatalyst](/creator/x/BPharmCatalyst) 2025-10-14T12:40Z 30.4K followers, 1971 engagements


"$OMER signed a definitive agreement to sell global rights of its MASP-3 inhibitor zaltenibart (OMS906) to Novo Nordisk for $340M upfront and near-term milestones with total deal value up to $2.1B plus tiered royalties giving Novo full control over development and commercialization in rare blood and kidney disorders. $GNPX $OMER $SPRC $EVAX $ENVB $SBFM $TOVX $SANA $AKTX $GANX See More Biotech Updates👇"  
[X Link](https://x.com/BPharmCatalyst/status/1978560064437825681) [@BPharmCatalyst](/creator/x/BPharmCatalyst) 2025-10-15T20:34Z 30.4K followers, 2096 engagements


"$ELUT agreed to sell its cardiac device business to Boston Scientific for $88M enabling debt elimination and a strategic shift toward its breast reconstruction-focused SimpliDerm franchise and drug-eluting pipeline aiming to improve financial stability and preserve shareholder value without dilution. $TRML $ELUT $CELU $RENB $REVB $TELO $XLO See More Biotech Updates👇 link"  
[X Link](https://x.com/BPharmCatalyst/status/1965513150960119968) [@BPharmCatalyst](/creator/x/BPharmCatalyst) 2025-09-09T20:30Z 30.4K followers, 1885 engagements


"$EVAX will present new biomarker and immune data for its personalized cancer vaccine EVX-01 in advanced melanoma at SITC 2025 complementing upcoming two-year efficacy results from its Phase X KEYTRUDA combination trial being presented at ESMO 2025. $PALI $ANRO $OVID $IMAB $BOLT $EVAX $APLIF $CLNN $SPRC $OCEA See More Biotech Updates👇"  
[X Link](https://x.com/BPharmCatalyst/status/1974210485022085549) [@BPharmCatalyst](/creator/x/BPharmCatalyst) 2025-10-03T20:30Z 30.4K followers, 3429 engagements


"$SHPH signed a letter of intent to acquire for $10M in cash and stock adding an AI-driven drug discovery platform that accelerates candidate identification and integrates autonomous workflows to enhance Shuttles therapeutic development capabilities. $SHPH $CARM $ARAY $CDT $ATYR $CDTX $ADTX $LITS $IVA $KIDS See More Pre-market Movers"  
[X Link](https://x.com/BPharmCatalyst/status/1976628859224154616) [@BPharmCatalyst](/creator/x/BPharmCatalyst) 2025-10-10T12:40Z 30.4K followers, 1657 engagements


"$GNPX announced preclinical data showing its lead candidate Reqorsa (quaratusugene ozeplasmid) induced apoptosis and demonstrated strong efficacy in ALK-EML4positive non-small cell lung cancer models. $GNPX $ATXS $NDRA $RCKT $GDTC $SBFM $EVAX $SNTI $CERO $IVVD See More Biotech Updates👇"  
[X Link](https://x.com/BPharmCatalyst/status/1978197105635143722) [@BPharmCatalyst](/creator/x/BPharmCatalyst) 2025-10-14T20:31Z 30.4K followers, 3442 engagements


"$GNPX announced preclinical data showing its lead candidate Reqorsa (quaratusugene ozeplasmid) induced apoptosis and demonstrated strong efficacy in ALK-EML4positive non-small cell lung cancer models. The data to be presented at the AACR-NCI-EORTC Molecular Targets Conference support Reqorsas potential as a gene therapy targeting the TUSC2 tumor suppressor pathway and its use in combination with ALK inhibitors. $GNPX $SCYX $KROS $EYPT $SPRC $EVAX $DMAC $IOBT $ELAB $ENTX See More Pre-market Movers"  
[X Link](https://x.com/BPharmCatalyst/status/1978440788246724827) [@BPharmCatalyst](/creator/x/BPharmCatalyst) 2025-10-15T12:40Z 30.4K followers, 12.5K engagements


"$RANI signed a $1.085B potential collaboration with Chugai receiving $10M upfront and up to $175M in milestones and royalties for the lead oral biologic using its RaniPill platform; alongside a $60.3M oversubscribed private placement and $28M in expected Chugai payments Rani is now funded into 2028 to advance its oral biologics pipeline. $RANI $ARTV $XRTX $KZR $ACHV $PLX $AKAN $IRON $RCEL $NIVF See More Pre-market Movers"  
[X Link](https://x.com/BPharmCatalyst/status/1979165574019068232) [@BPharmCatalyst](/creator/x/BPharmCatalyst) 2025-10-17T12:40Z 30.4K followers, 1684 engagements